Surrender Raina, MD
Cardiovascular Disease · Stockton, CANPI 1184662165
Payments from drug & device makers
Across 502 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Shockwave Medical, Inc$2K
- BD$1K
- E.r. Squibb & Sons, L.L.C.$552
- Boston Scientific$398
- Johnson & Johnson$347
- plus $2K from 30 others
What the payments were for
- Travel & lodging$3,15128%
- Food & beverage$7,89171%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 92 | $4,776 |
| Shockwave Medical, Inc | 103 | $1,710 |
| BD | 99 | $1,020 |
| E.r. Squibb & Sons, L.L.C. | 30 | $552 |
| Boston Scientific | 12 | $398 |
| Johnson & Johnson | 28 | $347 |
| Merck | 17 | $311 |
| Pfizer | 13 | $236 |
| Actelion Pharmaceuticals US, Inc. | 12 | $228 |
| Bard Peripheral Vascular, Inc. | 25 | $223 |
| Sanofi-aventis U.S. LLC | 10 | $176 |
| AstraZeneca | 7 | $155 |
| Atricure, Inc. | 1 | $146 |
| Bayer | 6 | $105 |
| Boehringer Ingelheim | 6 | $87 |
| Abbott | 4 | $86 |
| Cardiovascular Systems Inc. | 7 | $61 |
| Amgen | 4 | $59 |
| Philips North America LLC | 3 | $59 |
| Baxter Healthcare | 3 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Novartis | 3 | $37 |
| Biotronik Inc. | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $23 |
| Novo Nordisk | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Reflow Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,111 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 409 | $427,895 |
| XareltoRivaroxaban | 267 | $225,348 |
| EntrestoSacubitril/Valsartan | 130 | $139,340 |
| BrilintaTicagrelor | 130 | $96,287 |
| Repatha SureclickEvolocumab | 95 | $83,563 |
| JardianceEmpagliflozin | 21 | $26,948 |
| Tadalafil | 15 | $20,982 |
| Metoprolol Succinate | 983 | $17,371 |
| Praluent PenAlirocumab | 20 | $16,559 |
| MultaqDronedarone Hcl | 12 | $15,742 |
| OzempicSemaglutide | 15 | $14,024 |
| FarxigaDapagliflozin Propanediol | 15 | $9,363 |
| ClopidogrelClopidogrel Bisulfate | 568 | $6,160 |
| Atorvastatin Calcium | 590 | $5,829 |
| Rosuvastatin Calcium | 247 | $4,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $236 | $427,895409 claims |
| Johnson & JohnsonXarelto | $347 | $225,348267 claims |
| NovartisEntresto | $37 | $139,340130 claims |
| AstraZenecaBrilinta, Farxiga | $155 | $105,650145 claims |
| Boehringer IngelheimJardiance | $87 | $26,94821 claims |
| Sanofi-aventis U.S. LLCMultaq | $176 | $15,74212 claims |
| Novo NordiskOzempic | $21 | $14,02415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Stockton
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.